[Nfbf-l] Research for the blind with the actual data included!
Kirk Harmon
kvharmon54 at gmail.com
Wed Jan 14 22:32:58 UTC 2009
I'm sorry for not sending this information the first send!
Biochemical for Restoring Vision
People with certain forms of Leber congenital amaurosis
and retinitis pigmentosa have new hope for vision
restoration thanks to a treatment being developed by
QLT, Inc., a biopharmaceutical company in Vancouver,
Canada.
QLT recently launched a Phase I safety trial of the
treatment in approximately 18 adults.
The treatment, taken orally, is a synthetic retinoid
that is similar to a retinoid known as 11-cis-retinal.
This retinoid is essential to the visual cycle - a
complex chemical process in the retina that makes
vision possible - and is missing in the retinas of
people who have LCA caused by variations in RPE
and LRAT genes. The retinoid is also absent in a
small subset of people with retinitis pigmentosa.
The Foundation Fighting Blindness has funded
numerous preclinical studies - including projects
at the University of California, Los Angeles; the
University of Pennsylvania; and Case Western
Reserve University - to better understand the
visual cycle and the role of this missing retinoid
in the visual cycle.
In spring 2008 at FFB's San Francisco Dining in
the Dark fundraising event, Bob Butchofsky,
chief executive officer of QLT, received the
Foundation's Visionary Award for his numerous
contributions to eye health and the vision
community.
Smiles are nothing more than 30 second Vacations!
Kirk
Smiles are nothing more than 30 second Vacations!
More information about the NFBF-L
mailing list